187,984 Shares in Sarepta Therapeutics, Inc. $SRPT Purchased by Trexquant Investment LP

Key Points

• Trexquant Investment LP has made a new investment of approximately $12 million in Sarepta Therapeutics by acquiring 187,984 shares, which represents about 0.19% of the company's stock.
• Sarepta Therapeutics' stock received mixed reviews from analysts, with BMO Capital Markets raising its price target to $50, while TD Cowen set a lower price target of $24, reflecting varying perspectives on its market performance.
• The company reported a quarterly revenue of $611.09 million, significantly above analysts' expectations, showcasing a year-over-year growth of 68.4%.

Trexquant Investment LP purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 187,984 shares of the biotechnology company's stock, valued at approximately $11,997,000. Trexquant Investment LP owned approximately 0.19% of Sarepta Therapeutics at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Byrne Asset Management LLC purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth approximately $30,000. Center for Financial Planning Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth approximately $31,000. Pandora Wealth Inc. purchased a new stake in shares of Sarepta Therapeutics in the first quarter worth approximately $45,000. Brooklyn Investment Group lifted its position in shares of Sarepta Therapeutics by 450.4% in the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 590 shares in the last quarter. Finally, UMB Bank n.a. lifted its position in shares of Sarepta Therapeutics by 53.0% in the first quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 276 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on SRPT shares. William Blair reaffirmed an "outperform" rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 29th. Jefferies Financial Group lowered their target price on Sarepta Therapeutics from $40.00 to $35.00 and set a "buy" rating on the stock in a report on Thursday, July 24th. Cantor Fitzgerald reaffirmed a "neutral" rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. Leerink Partnrs lowered Sarepta Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, July 18th. Finally, Needham & Company LLC restated an "underperform" rating on shares of Sarepta Therapeutics in a research note on Monday, July 28th. Eight analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $43.50.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT traded down $0.14 during midday trading on Friday, reaching $18.20. 22,526,492 shares of the company traded hands, compared to its average volume of 10,716,794. The firm has a market cap of $1.78 billion, a PE ratio of -20.92 and a beta of 0.49. The stock's 50-day simple moving average is $17.72 and its 200-day simple moving average is $46.58. Sarepta Therapeutics, Inc. has a 12 month low of $10.41 and a 12 month high of $140.10. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company had revenue of $611.09 million during the quarter, compared to analyst estimates of $530.66 million. During the same period last year, the company posted $0.07 earnings per share. The firm's quarterly revenue was up 68.4% compared to the same quarter last year. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.